A Phase 3 interventional study of SD-101-6.0 cream in Epidermolysis Bullosa, sponsored by Scioderm, Inc.. Terminated at 30 sites in 12 countries. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2019-09-27.
Sponsored by Scioderm, Inc. (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one is the 3rd largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 3, and was the 11th registered.
86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.
Browse Epidermolysis Bullosa studies →10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 5–21
Paradigm Therapeutics · Sites in United States
Ages 28 days–12 yrs
Xinnate AB · Sites in United States, France, Greece and 4 more countries
Ages 4+
BioMendics, LLC · Sites in United States
Ages 2+
M. Peter Marinkovich · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.
This study: 1 Month and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 17 · Phase 3 8
First in 2007; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 15 across 68 interventional studies indexed under Epidermolysis Bullosa.
Median enrollment 16 across the 37 interventional studies, 60 across the 5 observational. Of the 26 that completed or were terminated, 16 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under Scioderm, Inc., one of the names counted as BioMarin Pharmaceutical. Under that name alone:
Scioderm, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
BioMarin Pharmaceutical has 5 studies filed under Epidermolysis Bullosa — fewer than ten, so there is no comparison to draw.
6 of the studies in Epidermolysis Bullosa with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482787Phase 3Paradigm TherapeuticsEfficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | 2027-05-17 |
| NCT07027345BioMendics, LLCA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | 2027-01 |
| NCT06834035M. Peter MarinkovichTargeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa | 2027-03 |
| NCT07050810Northwestern UniversityThera-Clean® Microbubbles System in Patients With Skin Diseases | 2027-06 |
| NCT06594393Xinnate ABA Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 42 studies in Epidermolysis Bullosa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).
This was an open label, multi-center extension study to assess the long-term safety of topically applied SD-101-6.0 in participants with simplex, recessive dystrophic, and junctional non-Herlitz EB. SD-101-6.0 was applied topically once a day to the entire body. The planned duration of treatment with SD-101-6.0 for Study SD-006 was up to 48 months, with a safety follow-up period of 30 days; however, the study was terminated early by the sponsor. The maximum study duration completed by at least 1 participant, treatment and safety follow-up, was 37 months.
Participants who successfully completed Study SD-005 had the option to rollover into Study SD-006. The screening/baseline visit (Visit 1) occurred at Visit 5 (approximately 90 days from baseline) of Study SD-005. The Body Surface Area (BSA) assessments of lesional skin and wound burden performed at Visit 5 (approximately 90 days from baseline) for Study SD-005 were utilized as the baseline assessments for Study SD-006. Participants returned for follow-up visits at Month 1 then every 3 months.
At each visit, assessments included BSA of lesional skin and wound burden. For target wounds that are not closed by the end of Study SD-005, the ARANZ picture and calculation of target wound area at the final visit for Study SD-005 was used as the baseline area size of the target wound for Study SD-006. These unhealed target wounds from Study SD-005 were assessed via ARANZ SilhouetteStar™ at each subsequent scheduled visit until the target wound was documented as closed. Closed wounds were assessed for scarring.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.
Drug: SD-101-6.0 cream
SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Also known as: Zorblisa, SD-101
Number Of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAEs were defined as adverse events that started or worsened on or after baseline visit.
Time frame: From baseline to 30 days after last application of study drug (up to a maximum of 37 months)
Change From Baseline In Body Surface Area Index (BSAI) Of Lesional Skin Up To Month 30
Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions to calculate the BSAI that would range from 0% to 100%. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline in BSAI was assessed every 3 months. Only participants with data available for analysis at each time point are presented.
Time frame: Baseline, up to Month 30
Change From Baseline In BSAI Of Total Body Wound Burden Up To Month 30
A wound was defined as an open area on the skin (that is, epidermal covering disrupted). Total body wound burden was calculated using BSAI; the percentage, ranging from 0% to 100%, of affected BSA was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions to calculate the BSAI that would range from 0% to 100%. The BSAI for total body wound burden was to be assessed by the same study physician at each visit for a particular participant. The mean change from baseline in total body wound burden was assessed every 3 months. Only participants with data available for analysis at each time point are presented.
Time frame: Baseline, up to Month 30
152 participants with epidermolysis bullosa (EB) were enrolled between 9 June 2015 and 5 July 2017 in this open-label, multi-center extension study. All enrolled participants had previously completed Study SD-005 (NCT02384460).
| Milestone | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 |
|---|---|---|
| Started | 75 | 77 |
| Received at least 1 dose of study drug | 75 | 77 |
| Completed | 0 | 0 |
| Not completed | 75 | 77 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Study terminated by sponsor | 36 | 43 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Withdrawal by subject | 34 | 29 |
| Withdrew: Lost to follow-up | 3 | 2 |
TEAEs were defined as adverse events that started or worsened on or after baseline visit.
| Participants | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 |
|---|---|---|
| Any TEAE | 51 | 58 |
| Any TEAE Related To Study Drug | 8 | 17 |
| Any Fatal TEAE | 0 | 0 |
| Any Serious TEAE | 11 | 14 |
| Any TEAE Leading To Discontinuation | 2 | 3 |
Lesional skin was defined as areas that contained any of the following: blisters, erosions, ulcerations, scabbing, bullae, or eschars, as well as areas that were weeping, sloughing, oozing, crusted, or denuded. The percentage, ranging from 0% to 100%, of affected body surface area (BSA) was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions to calculate the BSAI that would range from 0% to 100%. The BSA for lesional skin was to be assessed by the same study physician on each visit for a particular participant. The mean change from baseline in BSAI was assessed every 3 months. Only participants with data available for analysis at each time point are presented.
| Percentage of BSAI | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 |
|---|---|---|
| Month 1 | -0.76 ± 4.185 | -0.54 ± 5.398 |
| Month 3 | -1.87 ± 5.999 | -1.21 ± 6.457 |
| Month 6 | -1.77 ± 6.015 | -1.35 ± 6.813 |
| Month 9 | -2.48 ± 9.436 | 0.31 ± 10.117 |
| Month 12 | -3.35 ± 9.566 | 0.44 ± 10.327 |
| Month 15 | -1.90 ± 7.337 | 2.15 ± 12.546 |
| Month 18 | -2.46 ± 5.275 | -4.24 ± 8.207 |
| Month 21 | -3.06 ± 5.869 | -1.58 ± 10.442 |
| Month 24 | -1.63 ± 5.647 | -0.64 ± 5.981 |
| Month 27 | -1.87 ± 4.405 | -0.16 ± 6.514 |
| Month 30 | -2.77 ± 5.465 | 3.37 ± 10.706 |
A wound was defined as an open area on the skin (that is, epidermal covering disrupted). Total body wound burden was calculated using BSAI; the percentage, ranging from 0% to 100%, of affected BSA was recorded for each defined body region (that is, head/neck, upper limbs, trunk \[includes groin\], and lower limbs), multiplied by the weighting factor, then summed for all body regions to calculate the BSAI that would range from 0% to 100%. The BSAI for total body wound burden was to be assessed by the same study physician at each visit for a particular participant. The mean change from baseline in total body wound burden was assessed every 3 months. Only participants with data available for analysis at each time point are presented.
| Percentage of BSAI | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 |
|---|---|---|
| Month 1 | -1.75 ± 4.891 | 0.07 ± 4.044 |
| Month 3 | -1.52 ± 5.343 | -0.80 ± 3.001 |
| Month 6 | -1.54 ± 4.322 | -0.48 ± 3.595 |
| Month 9 | -1.82 ± 6.083 | -0.42 ± 3.586 |
| Month 12 | -1.38 ± 5.497 | -0.13 ± 3.211 |
| Month 15 | -0.15 ± 4.511 | 0.26 ± 3.030 |
| Month 18 | -1.12 ± 3.053 | -1.31 ± 4.665 |
| Month 21 | -1.44 ± 3.150 | -0.28 ± 5.507 |
| Month 24 | -0.68 ± 3.890 | -0.01 ± 2.898 |
| Month 27 | -0.43 ± 2.924 | 0.31 ± 3.615 |
| Month 30 | -1.55 ± 2.883 | 1.69 ± 5.933 |
Collected over From baseline to 30 days after last application of study drug (up to a maximum of 37 months).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SD-101-6.0 to SD-101-6.0 | 0/75 (0%) | 11/75 (14.7%) | 44/75 (58.7%) |
| Placebo to SD-101-6.0 | 0/77 (0%) | 14/77 (18.2%) | 51/77 (66.2%) |
| Event | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/75 | 2/77 |
| Oesophageal stenosisGastrointestinal disorders | 1/75 | 2/77 |
| Skin infectionInfections and infestations | 0/75 | 2/77 |
| PericarditisCardiac disorders | 1/75 | 0/77 |
| Congenital megaureterCongenital, familial and genetic disorders | 1/75 | 0/77 |
| KeratitisEye disorders | 1/75 | 0/77 |
| ConstipationGastrointestinal disorders | 1/75 | 1/77 |
| DysphagiaGastrointestinal disorders | 1/75 | 0/77 |
| FaecalomaGastrointestinal disorders | 1/75 | 0/77 |
| Implant site infectionInfections and infestations | 1/75 | 0/77 |
| Event | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 |
|---|---|---|
| Skin infectionInfections and infestations | 6/75 | 12/77 |
| NasopharyngitisInfections and infestations | 10/75 | 6/77 |
| PyrexiaGeneral disorders | 5/75 | 10/77 |
| Wound infectionInfections and infestations | 3/75 | 6/77 |
| PruritusSkin and subcutaneous tissue disorders | 3/75 | 6/77 |
| AnaemiaBlood and lymphatic system disorders | 5/75 | 5/77 |
| ConstipationGastrointestinal disorders | 5/75 | 3/77 |
| BronchitisInfections and infestations | 5/75 | 1/77 |
| Upper respiratory tract infectionInfections and infestations | 4/75 | 5/77 |
| Wound infection bacterialInfections and infestations | 2/75 | 5/77 |
Intent-to-treat (ITT) population: all participants who rolled over from Study SD-005.
| Age, Continuous(years) | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 | Total |
|---|---|---|---|
| Mean | 14.18 ± 13.381 | 14.36 ± 13.599 | 14.27 ± 13.447 |
| Sex: Female, Male(Participants) | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 | Total |
|---|---|---|---|
| Female | 28 | 45 | 73 |
| Male | 47 | 32 | 79 |
| Ethnicity (NIH/OMB)(Participants) | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 13 | 18 |
| Not Hispanic or Latino | 67 | 60 | 127 |
| Unknown or Not Reported | 3 | 4 | 7 |
| Race/Ethnicity, Customized(Participants) | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 | Total |
|---|---|---|---|
| White/Caucasian | 65 | 63 | 128 |
| Black or African-American | 4 | 3 | 7 |
| Asian | 3 | 7 | 10 |
| American Indian or Alaskan Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific | 0 | 0 | 0 |
| Other | 1 | 1 | 2 |
| Unknown | 2 | 3 | 5 |
| EB Type(Participants) | SD-101-6.0 to SD-101-6.0 | Placebo to SD-101-6.0 | Total |
|---|---|---|---|
| Simplex | 9 | 7 | 16 |
| Recessive Dystrophic | 53 | 56 | 109 |
| Junctional Non-Herlitz | 13 | 14 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Sep 2018, 38 months.
Results were first posted in Aug 2019, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nelitolimod